Canopy Growth launches Spectrum Australia with support from the Victoria State Government Canada NewsWire SMITHS FALLS, ON and MELBOURNE, Australia, April 25, 2018 SMITHS FALLS, ON and MELBOURNE, Australia, April 25, 2018 /CNW/ - Canopy Growth Corporation (TSX: WEED) ("Canopy Growth" or the "Company") is pleased to join the Victoria State Government in announcing the launch of the newest member of the Canopy Growth family, Spectrum Cannabis Australia ("Spectrum" or "Spectrum Australia").
Minister for Agriculture, the Hon. Jaala Pulford, alongside Ben Quirin, Managing Director of Spectrum Australia, announced the Company will invest up to $16 million AUD (~$16 million CAD) in the State of Victoria over the next four years to establish Spectrum's Asia-Pacific (APAC) headquarters and research and development facility. "The State Government of Victoria has been an outstanding partner and welcomed our investment in the region with a shared passion for innovation in the medical cannabis industry," said Ben Quirin, Managing Director, Spectrum Australia. "Victoria is now home for Spectrum as we introduce our world renowned medical cannabis products to the State, across Australia, and throughout the entire APAC region as jurisdictions establish legal, regulated medical cannabis regimes." The Victoria facility will enable domestic cultivation and production of high quality medical cannabis for patients while serving as a distribution hub for other jurisdictions in APAC. It will also operate as the APAC Research and Development Center for the Company, supporting the ongoing research collaboration between Spectrum Australia and Agriculture Victoria on innovations in medical cannabis cultivation and production. "Collaborating with international experts on cultivation and manufacturing will build Victoria's capacity to develop our medicinal cannabis industry to be able to supply reliable and high quality medicinal cannabis products," said Minister for Agriculture, the Hon. Jaala Pulford. The launch of Spectrum Australia builds on Canopy Growth's leadership position in the global medical cannabis space. Spectrum Australia's priority is to improve the lives of patients. This goal will be accomplished by focusing on three core areas: Ensuring an affordable and consistent supply of medical cannabis is available to patients in Australia Building production and research infrastructure in Australia Engaging in rigorous evidence-based physician and pharmacist education to ensure patients' access needs are met This week Canopy Growth renewed its commitment to Australian partner, AusCann (ASX:AC8). Together with the State Government of Victoria and our strong local partner Spectrum Australia is committed to building an industry for the benefit of patients and healthcare professionals throughout APAC. Spectrum Cannabis - Medical Cannabis. Simplified. Learn more by visiting spectrumcannabis.com.au About Spectrum Cannabis Spectrum is an international cannabis business dedicated to improving the lives of patients and increasing cannabinoid knowledge within physician communities around the world. Its colour-coded strain classification system is available in Canada with operations underway in the European Union and South America, and Australia. Spectrum products are available in a range of potencies and formats designed to simplify the dialogue around strength and dosage by categorizing medical cannabis according to THC and CBD levels. Spektrum Germany Gmbh processes cannabis for sale in Germany in a GMP-certified facility and then distributes products to hundreds of German pharmacies. Spectrum Denmark is a partnership between Canopy Growth and Danish Cannabis. Through the partnership, Spectrum Denmark is developing a large-scale greenhouse facility in the city of Odense. Learn more at www.spectrumcannabis.com.au About Canopy Growth Corporation Canopy Growth is a world-leading diversified cannabis and hemp company, offering distinct brands and curated cannabis varieties in dried, oil and Softgel capsule forms. From product and process innovation to market execution, Canopy Growth is driven by a passion for leadership and a commitment to building a world-class cannabis company one product, site and country at a time.
hi leute, gerade gesehen. ich bin schon länger in auscann investiert. bei auscann ist alles am laufen. https://www.auscann.com.au/investor-centre/asx-announcements/2018.html der kurs ist leider nach unten gegangen, das geht aber wieder hoch. usa-chile-deutschland-australien, auscann wächst und wächst. sobald sie umsätze haben geht es los. die medizin bei auscann geht voran. dies ist eine aktie für in rente gehen. lasst euch überraschen. keine kaufempfehlung nur meine persönliche meinung. gruß kiba
AusCann Effects Board Changes 4 November 2019 ? Leading medical cannabis company AusCann Group Holdings Limited (ASX:AC8) (AusCann or ?the Company?) announces that further to the Board renewal process announced on 28 October 2019, the Company has appointed Mr Christopher Mews as a Non-Executive Director of AusCann. Mr Mews is the nominee from AusCann?s largest shareholder, Merchant Funds Management, with his appointment to be effective from 1 December 2019. Mr Mews is an experienced non-executive director with over 20 years in the financial services sector, having held senior positions in finance, corporate secretarial and compliance in listed and unlisted companies. Mr Mews is currently the Chief Financial Officer and Company Secretary of Merchant Group Pty Ltd, a Perth based financial services firm that provides funds management and corporate finance services, with investment experience both in Australia and internationally in the medical cannabis sector. Prior to Merchant Group, he was the Chief Financial Officer and Company Secretary of listed biotech Company Polynovo Limited (ASX:PNV), and is currently Company Secretary and Non-Executive Director of VPCL Limited (ASX:VPC). Mr Mews holds a Bachelor of Business majoring in Accounting and is a Certified Practising Accountant, a Chartered Company Secretary and member of the Governance Institute of Australia. The Company also advises that Dr Paul MacLeman has resigned as an Executive Director of AusCann effective today. Dr MacLeman joined the AusCann Board as a part of the CEO leadership transition in late 2018, and with that transition to the Company?s new CEO Mr Ido Kanyon having now taken place, it is appropriate for him to step down. The Board thanks Dr MacLeman for standing in as interim CEO and Director during this important transition period. ENDS